text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 122320-73-4 | Product Number: R0106

Rosiglitazone


Purity: >98.0%(T)(HPLC)
Synonyms:
Documents:
200MG
¥5,500
≥20  4   ≥20 
1G
¥19,400
≥20  6   ≥20 
Available Stock: Prompt shipment (for products) in Saitama/Hyogo warehouse. Stock in other WH: 2-3 Business Days
* Please contact us if you need further information.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number R0106
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__1__8H__1__9N__3O__3S = 357.43  
Physical State (20 deg.C) Solid
Storage Temperature 0-10°C
Condition to Avoid Heat Sensitive
CAS RN 122320-73-4
Reaxys Registry Number 7082202
PubChem Substance ID 253659589
Merck Index (14) 8265
MDL Number

MFCD00871760

Specifications
Appearance White to Light yellow powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Melting point 154.0 to 158.0 °C
Properties (reference)
Melting Point 156 °C
GHS
Related Laws:
RTECS# XJ5813850
Transport Information:
Application
Rosiglitazone: An Agonist at the Peroxisome Proliferator-Activated Receptor of the Gamma Subtype (PPARγ)

Rosiglitazone, a thiazolidinedione, is an agonist at the peroxisome proliferator-activated receptor of the gamma subtype (PPARγ), a transcription-regulating receptor. PPAR receptors are found in peripheral tissues important for insulin action. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. Therefore, rosiglitazone decreases insulin resistance in the periphery tissues and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. And recently, it has been reported that rosiglitazone is associated with cardiovascular problems. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents